Federal filings show Boston Scientific spinal cord stimulator lawsuits have been centralized as MDL No. 3181 for coordinated pretrial proceedings.
The filings allege injuries from implanted pain devices but do not establish defect, causation, liability, or any settlement. A spinal cord stimulator is an implanted device that sends electrical pulses to interrupt chronic-pain signals. The current proceedings affect implanted chronic-pain patients whose complaints claim device problems and later medical care.
Table of Contents
- How the federal cases were centralized
- What implanted patients allege in complaints
- What the FDA recall actually covers
- Why some claims face a preemption barrier
- What the proceedings do not establish
How the federal cases were centralized
The Judicial Panel on Multidistrict Litigation created MDL No. 3181 on June 5, 2026, before Judge Josephine L. Staton in the Central District of California, according to the JPML transfer order hosted by Saiontz & Kirk. Centralization groups related federal cases for shared discovery and pretrial rulings.
Individual cases remain separate lawsuits. The MDL started with 10 Boston Scientific cases from four districts. OpenClassActions reported 41 pending actions by October 1, 2026. The Panel refused to create one industry-wide stimulator MDL covering Abbott, Nevro and Medtronic, Law360 UK reported, because manufacturer-specific regulatory histories and discovery would not overlap.
What implanted patients allege in complaints
Filed complaints concern people living with implanted stimulators for chronic pain, according to the Lawsuit Information Center from Miller & Zois. The complaints allege device-related harm followed by added treatment, including repeat procedures.
These are allegations in pleadings, not court findings. The alleged problems include:.
- shocks, burns, or painful stimulation
- inadequate pain relief
- lead migration or fracture
- revision or explant surgery
What the FDA recall actually covers
The FDA action addresses unused Infinion CX leads, not all Boston Scientific stimulators. FDA classified the removal of unused leads as its most serious Class I recall after mechanical stress at the anchor site caused high impedance or fractures requiring intervention, according to the FDA MedWatch bulletin.
Class I means FDA found a reasonable chance of serious harm. Boston Scientific reported 1,081 serious injuries and zero deaths tied to that lead issue as of May 27, 2026. FDA said already-implanted devices were not affected and should not be removed preventively, according to the same FDA MedWatch bulletin.
Why some claims face a preemption barrier
A Michigan federal judge dismissed a WaveWriter stimulator suit in February 2026. The court held the state-law claims were preempted because the Class III device went through FDA premarket approval, according to the Lawsuit Information Center account from Miller & Zois. Premarket approval is FDA's most demanding device review.
Preemption can block state tort claims that would impose requirements different from federal requirements. That defense turns on the device history and the exact claims pleaded. It does not decide whether any patient was injured.
What the proceedings do not establish
MDL coordination does not certify a class and does not award damages. OpenClassActions reports that no manufacturer has been found liable, no class has been certified, and there is no settlement or claim form.
Complaints and coordination alone do not prove causation or defect. Patients with concerns can take practical steps now:.
- seek prompt care for new pain, shocks, burns, or loss of relief
- keep the implant card, operative reports, programming visits, and imaging
- list revision, explant, infection care, and out-of-pocket costs
- ask a products-liability attorney about deadlines and records before acting